RNA

Total RNA was prepared from cell line WM1789. WM1789 is a human melanoma cell line originally isolated from a human primary radial growth phase melanoma. WM1789 cells produce xenograft tumors when injected into immunocompromised mice. This line carries the K601E and S363F mutation in BRAF, and is hemizygous deleted for PTEN.

Total RNA was prepared from cell line WM1789. WM1789 is a human melanoma cell line originally isolated from a human primary radial growth phase melanoma. WM1789 cells produce xenograft tumors when injected into immunocompromised mice. This line carries the K601E and S363F mutation in BRAF, and is hemizygous deleted for PTEN.

Total RNA was prepared from cell line WM1791C. WM1791C is a metastatic human melanoma cell line. This cell line features the wild type KRAS and KRAST501, KRASE62K mutation. This cell line also expresses a K22Q mutation in CDK4. The K22Q mutation results in an amino acid substitution at position 22 in CDK4, from a lysine (K) to a glutamine (Q). This cell line is wild type for BRAF, and c-KIT genes. WM1791C cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1791C. WM1791C is a metastatic human melanoma cell line. This cell line features the wild type KRAS and KRAST501, KRASE62K mutation. This cell line also expresses a K22Q mutation in CDK4. The K22Q mutation results in an amino acid substitution at position 22 in CDK4, from a lysine (K) to a glutamine (Q). This cell line is wild type for BRAF, and c-KIT genes. WM1791C cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1791C. WM1791C is a metastatic human melanoma cell line. This cell line features the wild type KRAS and KRAST501, KRASE62K mutation. This cell line also expresses a K22Q mutation in CDK4. The K22Q mutation results in an amino acid substitution at position 22 in CDK4, from a lysine (K) to a glutamine (Q). This cell line is wild type for BRAF, and c-KIT genes. WM1791C cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1799. WM1799 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1799 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1799. WM1799 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1799 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1799. WM1799 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1799 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1819. WM1819 is a human melanoma cell line that displays mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1819 cells produce xenograft tumors when injected into immunocompromised mice.